Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer.
Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s share is listed on Nasdaq Stockholm.
Latest press releases
New visual identity
Most welcome to our new website and our new visual identity! The identity has been created partly to give us a more powerful and unified expression in all communication, but also to give us a more human approach. Our ambition is to become a more distinctive brand that conveys the essence of our business, and this identity is an important tool to achieve that.
2025-10-08
CEO interview
Isofol’s CEO, Petter Segelman Lindqvist, was interviewed by Dagens Industri Investor Relations for an update on the company.
2025-09-30
Isofol successfully completed the second level in the dose escalating clinical study with arfolitixorin
For investors
Upcoming Events
- October 17, 2025 - October 21, 2025
ESMO 2025
ESMO 2025 is getting closer. Isofol´s CEO, Petter Segelman Lindqvist, and CMO, Roger Tell will be present in Berlin during October 17-21. - November 12, 2025 - November 12, 2025
Interim report July-September 2025 - December 03, 2025 - December 03, 2025
Redeye Life Science Day 2025
Isofol deltar under dagen med en kort presentation följt av en frågestund med Redeyes analytiker.
Latest reports and presentations
